Methods: We conducted an analysis of retrospective data extracted from the medical records of adult patients (more than 18 years of age) who underwent their first allogenic SCT between January 1, 2010 and December 30, 2016 at the University of Kansas Health System. Patients were followed for CDI events between day -10 to day +100 of allogenic transplant. Diagnosis and staging of aGvHD were determined based on standardized aGvHD grading scale utilizing clinical and pathological information between day 0 and day +100. Analysis included descriptive statistics, multivariable logistic regression, and survival analysis with CDI as a time-dependent variable.
Results:: A total of 656 allogenic SCT recipients were included in the analysis. Of the total sample, 419 (64%) developed aGvHD within the first 100 days. CDI was observed in 112 (17%) of all allogenic SCT recipients, 72 (64%) of CDI cases developed prior to the onset of aGvHD. Fidaxomicin was used in the treatment of 57 (50%), whereas, vancomycin was used in 53 (47%) of CDI cases. On unadjusted analysis, CDI was associated with aGvHD (p = 0.0036), high grade aGvHD (p = 0.0132), and GI aGvHD (p = 0.0003). On multivariate survival analysis, the following predictors were associated with aGvHD: CDI (adjusted Hazard Ratio (aHR) = 1.44, p = 0.0047), matched unrelated donor versus matched related donor transplant type (aHR = 1.40, p = 0.0023), myeloablative versus reduced intensity conditioning (aHR = 1.87, p < 0.0001). This was consistent with the stepwise logistic regression model.
Conclusion: Allogenic SCT recipients with CDI have a higher risk of aGvHD compared to those without CDI.
W. El Atrouni, None
M. Telfah, None
G. Gao, None
J. He, None
L. Clough, None
See more of: Poster Abstract Session